Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99–100

Adrian Pilatz; Steven MacLennan; Roderick C.N. van den Bergh; Rajan Veeratterapillay; Muhammad Imran Omar; Yuhong Yuan; Phillip Cornford; Gernot Bonkat

doi:10.1016/j.eururo.2023.09.008

Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99–100

Adrian Pilatz^* (Corresponding Author), Steven MacLennan, Roderick C.N. van den Bergh, Rajan Veeratterapillay, Muhammad Imran Omar, Yuhong Yuan, Phillip Cornford, Gernot Bonkat

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

4 Downloads (Pure)

Abstract

We welcome the opportunity to respond to the Platinum Opinion by Dr. Mian [1]. In 2015, the European Association of Urology (EAU) Urological Infections Guideline Panel initiated a systematic review of randomised controlled trials (RCTs) to demonstrate how infectious complications of prostate biopsy can be reduced. The evidence was published in 2020 in two parts, covering antibiotic and nonantibiotic interventions [2], [3]. Since then, the evidence has been updated every year to ensure that the EAU guidelines reflect the most up-to-date evidence for this important diagnostic procedure.

Original language	English
Pages (from-to)	313-314
Number of pages	2
Journal	European Urology
Volume	85
Issue number	3
Early online date	23 Sept 2023
DOIs	https://doi.org/10.1016/j.eururo.2023.09.008
Publication status	Published - Mar 2024

Keywords

Biopsy
Humans
Male
Nitrosamines
Prostate
Prostatic Neoplasms

Access to Document

10.1016/j.eururo.2023.09.008Licence: Unspecified

Pilatz_etal_EU_European_Association_Of_AAM
This accepted author manuscript has been made open access under the University of Aberdeen Rights Retention Policy. It is available under a Creative Commons Attribution license https://creativecommons.org/licenses/by/4.0/ Final published version available at https://doi.org/10.1016/j.eururo.2023.09.008
Accepted author manuscript, 132 KBLicence: CC BY

Cite this

@article{503e6b85505c4684aa8d262eba6e448b,

title = "Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99–100",

abstract = "We welcome the opportunity to respond to the Platinum Opinion by Dr. Mian [1]. In 2015, the European Association of Urology (EAU) Urological Infections Guideline Panel initiated a systematic review of randomised controlled trials (RCTs) to demonstrate how infectious complications of prostate biopsy can be reduced. The evidence was published in 2020 in two parts, covering antibiotic and nonantibiotic interventions [2], [3]. Since then, the evidence has been updated every year to ensure that the EAU guidelines reflect the most up-to-date evidence for this important diagnostic procedure.",

keywords = "Biopsy, Humans, Male, Nitrosamines, Prostate, Prostatic Neoplasms",

author = "Adrian Pilatz and Steven MacLennan and {van den Bergh}, {Roderick C.N.} and Rajan Veeratterapillay and Omar, {Muhammad Imran} and Yuhong Yuan and Phillip Cornford and Gernot Bonkat",

year = "2024",

month = mar,

doi = "10.1016/j.eururo.2023.09.008",

language = "English",

volume = "85",

pages = "313--314",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Reply to Badar M. Mian. Prostate Biopsy

T2 - Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99–100

AU - Pilatz, Adrian

AU - MacLennan, Steven

AU - van den Bergh, Roderick C.N.

AU - Veeratterapillay, Rajan

AU - Omar, Muhammad Imran

AU - Yuan, Yuhong

AU - Cornford, Phillip

AU - Bonkat, Gernot

PY - 2024/3

Y1 - 2024/3

N2 - We welcome the opportunity to respond to the Platinum Opinion by Dr. Mian [1]. In 2015, the European Association of Urology (EAU) Urological Infections Guideline Panel initiated a systematic review of randomised controlled trials (RCTs) to demonstrate how infectious complications of prostate biopsy can be reduced. The evidence was published in 2020 in two parts, covering antibiotic and nonantibiotic interventions [2], [3]. Since then, the evidence has been updated every year to ensure that the EAU guidelines reflect the most up-to-date evidence for this important diagnostic procedure.

AB - We welcome the opportunity to respond to the Platinum Opinion by Dr. Mian [1]. In 2015, the European Association of Urology (EAU) Urological Infections Guideline Panel initiated a systematic review of randomised controlled trials (RCTs) to demonstrate how infectious complications of prostate biopsy can be reduced. The evidence was published in 2020 in two parts, covering antibiotic and nonantibiotic interventions [2], [3]. Since then, the evidence has been updated every year to ensure that the EAU guidelines reflect the most up-to-date evidence for this important diagnostic procedure.

KW - Biopsy

KW - Humans

KW - Male

KW - Nitrosamines

KW - Prostate

KW - Prostatic Neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85172032569&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2023.09.008

DO - 10.1016/j.eururo.2023.09.008

M3 - Editorial

C2 - 37748970

SN - 0302-2838

VL - 85

SP - 313

EP - 314

JO - European Urology

JF - European Urology

IS - 3

ER -

Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99–100

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this